Juniper Pharmaceuticals

The Company has a successful history in developing pharmaceutical products, including Crinone® 8% (progesterone gel), which is commercially available in the United States and over 90 countries around the world.

We are currently developing several product candidates using our segmented intravaginal ring (IVR) technology. The most advanced of these is JNP-0101, an oxybutynin IVR for the treatment of overactive bladder in women.

We are leveraging the in-house pharmaceutical development, clinical trial supply manufacturing, and analytical capabilities of Juniper Pharma Services to advance an internal product pipeline, while also providing valuable intellectual property-related consultative services to our pharmaceutical industry customers.

Juniper is positioned for success with a highly experienced leadership team in combination with a solid balance sheet and strong cash flows to advance a proprietary pipeline for long term value creation.

Boston, US
Size (employees)
139 (est)+33%
Juniper Pharmaceuticals was founded in 1986 and is headquartered in Boston, US

Juniper Pharmaceuticals Office Locations

Juniper Pharmaceuticals has an office in Boston
Boston, US (HQ)
33 Arch St

Juniper Pharmaceuticals Metrics

Juniper Pharmaceuticals Financial Metrics

Juniper Pharmaceuticals's revenue was reported to be $54.6 m in FY, 2016 which is a 45% increase from the previous period.

Revenue (FY, 2016)

$54.6 m

Revenue growth (FY, 2015 - FY, 2016), %


Gross profit (FY, 2016)

$30.3 m

Gross profit margin (FY, 2016), %


Net income (FY, 2016)

$6 m

EBIT (FY, 2016)

$5.3 m

Market capitalization (19-May-2017)

$43.9 m

Closing share price (19-May-2017)


Cash (31-Dec-2016)

$21 m


$23.3 m
Juniper Pharmaceuticals's current market capitalization is $43.9 m.
FY, 2013FY, 2014FY, 2015FY, 2016


$29.2 m$32.5 m$37.6 m$54.6 m

Revenue growth, %


Cost of goods sold

$13.3 m$17.7 m$21.4 m$24.3 m

Gross profit

$16 m$14.8 m$16.1 m$30.3 m

Gross profit Margin, %


Operating expense total

$10.1 m$11 m$18.7 m$25 m


$5.9 m$3.8 m($2.5 m)$5.3 m

EBIT margin, %


Interest expense

($97 k)

Interest income

($97 k)

Pre tax profit

$6.7 m$4.4 m($2.1 m)$6 m

Income tax expense

$22.6 k$988 k$5 k$91 k

Net Income

$6.7 m$3.4 m($2.1 m)$6 m
FY, 2013FY, 2014FY, 2015FY, 2016


$20.7 m$16.8 m$13.9 m$21 m

Accounts Receivable

$7.2 m$5.3 m


$2.6 m$3.2 m$3.6 m$5.6 m

Current Assets

$32.2 m$26.4 m$26.7 m$34.7 m


$13.2 m$13 m$12.9 m$13.4 m


$11.2 m$10.5 m$10 m$8.3 m

Total Assets

$60.1 m$52.2 m$51.4 m$57.6 m

Accounts Payable

$2.8 m$2.9 m$2 m$3.9 m

Total Debt

$500.3 k$486 k$476 k$408 k

Current Liabilities

$6.3 m$5.9 m$7.7 m$15 m

Additional Paid-in Capital

$287 m$287.7 m$289.5 m$290.6 m

Retained Earnings

($241.7 m)($238.3 m)($240.4 m)($237.4 m)

Total Equity

$46.9 m$40.9 m$39.4 m$39.8 m

Debt to Equity Ratio

0 x0 x0 x0 x

Debt to Assets Ratio

0 x0 x0 x0 x

Financial Leverage

1.3 x1.3 x1.3 x1.4 x
FY, 2013FY, 2014FY, 2015FY, 2016

Net Income

$6.7 m$3.4 m($2.1 m)$6 m

Depreciation and Amortization

$919.1 k$2 m$1.9 m$1.9 m

Accounts Receivable

($2.3 m)$1.7 m($2.5 m)$192 k


$46.5 k($619 k)($424 k)($2 m)

Accounts Payable

$314.8 k$91 k($925 k)$1.6 m

Cash From Operating Activities

$7.1 m$6.9 m($891 k)$11.2 m

Purchases of PP&E

($522.4 k)($2 m)($1.7 m)($3.6 m)

Cash From Investing Activities

$315.1 k($2 m)($1.7 m)($3.6 m)

Short-term Borrowings

($72.3 k)($245 k)($238 k)($226 k)

Dividends Paid

($27.5 k)($28 k)($28 k)($28 k)

Cash From Financing Activities

($89.1 k)($8.7 m)($206 k)($254 k)

Interest Paid

$24.9 k$120 k$101 k$85 k

Income Taxes Paid

$3 k$3 k$2 k$2 k
Y, 2016


4.4 x


2.1 x


$519.7 k

Financial Leverage

1.4 x

Juniper Pharmaceuticals Operating Metrics

FY, 2016

Patents Issued


Juniper Pharmaceuticals Market Value History

Juniper Pharmaceuticals Job Categories

Juniper Pharmaceuticals Company Life

You may also be interested in